X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Fintepla (fenfluramine) increase extracellular levels of serotonin through interaction with serotonin transporter proteins, and exhibit agonist activity at serotonin 5HT-2 receptors. It is being investigated for seizures associated with Dravet syndrome.
Lead Product(s): Fenfluramine Hydrochloride
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Fenfluramine has demonstrated efficacy in the most difficult to treat seizure types, including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground with a high likelihood of injury.
Lead Product(s): Fenfluramine Hydrochloride
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
The transaction will broaden and build upon UCB's role as a leader in rare forms of epilepsy after adding FINTEPLA® to UCB's existing product line and complementing existing medicines and expanding clinical development pipeline of epilepsy.
Lead Product(s): Fenfluramine Hydrochloride
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition January 19, 2022
Details:
Zogenix intends to use the net proceeds from the offering to fund development and commercialization of Fintepla in Dravet syndrome, Lennox-Gastaut syndrome, and other potential indications, to fund the development of MT1621 in TK2 deficiency.
Lead Product(s): Fenfluramine Hydrochloride
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $222.7 million Upfront Cash: Undisclosed
Deal Type: Financing October 05, 2020
Details:
Zogenix intends to use the net proceeds from the offering to fund development and commercialization of Fintepla in Dravet syndrome, Lennox-Gastaut syndrome, to fund the development of MT1621 in TK2 deficiency and other general corporate purposes.
Lead Product(s): Fenfluramine Hydrochloride
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 23, 2020
Details:
FINTEPLA at 0.7 mg/kg/day achieved a 64.8% greater reduction in mean monthly convulsive seizures compared to placebo and FINTEPLA at a lower dose of 0.2 mg/kg/day achieved a 49.9% greater reduction in mean monthly convulsive seizures compared to placebo.
Lead Product(s): Fenfluramine Hydrochloride
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
